Has the CAR-T therapy been engineered to eliminate expression of the endogenous T-cell receptor ... Engraftment of CAR-T in tumor-bearing immunocompromised mice (e.g., NSG, NCG mice).

The Charles River models NCG-hIL2 and NCG-hIL15 are built on the NCG background, which lacks functional/mature T, B, and NK cells, and has reduced macrophage and dendritic cell function. NCG-hIL2 ...

Finally, to assess long-term toxicity, the researchers followed mice that received CARD11-PIK3R3 T cell therapies, including those that were part of the dose-response study, for up to 418 days.

Regulatory T-cell therapy calms autoimmune response from gluten-sensitive T cells in mice By Darren Incorvaia Mar 20, 2025 7:16am ...

Treating cultured T cells with the engineered proteins did not have a detrimental effect on T cell function, but induced LCK enzyme activity. From the collection of engineered proteins, the ...

An immunofluorescence image of an aged mouse liver. Expression of β-galactosidase (white) and uPAR (yellow) in senescent cells serve as target for engineered CAR T cells. Elimination of these ...

Mice normally live about two years, and research found the uPAR-targeting CAR T cells persisted and expanded for more than 15 months in mice as they grew from youth into older age.

Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models. Clinical Cancer Research , 2022; clincanres.0947.2021 DOI: 10.1158 ...

A CAR was initially developed with mouse IL-5 as the antigen-binding moiety. T-cells expressing this IL-5 CAR, which were eventually referred to as 5T cells, were found to effectively deplete IL-5 ...

Mice normally live about two years, and research found the uPAR-targeting CAR T cells persisted and expanded for more than 15 months in mice as they grew from youth into older age. “In some ways, ...